Rexgenero appoints Huw Jones as a non-executive director

Huw Jones Rexgenero has announced that Huw Jones has joined the company’s board as a non-executive director, and will chair the company’s remuneration committee. This follows the recent appointment of David Horn Solomon as chairman of Rexgenero’s Board. Huw is currently CEO of Chronos Therapeutics Limited (Chronos), a spin out from the [...]

2020-02-17T13:39:13+00:00February 17th, 2020|Tags: , |

First UK site opens for clinical trial of novel patient-specific regenerative cell therapy for chronic limb-threatening ischaemia

Image credit: Rexgenero The first UK clinical trial site for the treatment of diabetic patients with chronic limb-threatening ischaemia using a novel patient-specific regenerative therapy has opened for patient recruitment at the University Hospital of Wales in Cardiff. The site will be evaluating REX-001 (Rexgenero) in two phase III trials codenamed the [...]

2019-12-06T15:09:13+00:00December 6th, 2019|Tags: , , , |